- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure
Dapagliflozin was shown to not only benefit patients at risk of heart failure, both with and without diabetes, but treat patients with established heart failure as well, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Dapagliflozin was shown to not only benefit patients at risk of heart failure, both with and without diabetes, but treat patients with established heart failure as well, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Transcript
Given the benefits that DAPA-HF revealed in preventing the worsening of heart failure in patients without diabetes, what is the potential role of dapagliflozin in primary prevention?
Dapagliflozin has 2 key roles when it comes to thinking about heart failure. The first is we have very strong evidence that dapagliflozin, and the whole SGLT2 inhibitor family, reduce the risk of incident heart failure. So, if you’ve got type 2 diabetes, 1 of the major risks you face is developing heart failure, and dapagliflozin, like other SGLT2 inhibitors, unequivocally reduces that risk substantially. What's new is that we now know that dapagliflozin is also a treatment for established heart failure. So, moving from prevention to treatment, we can treat patients with heart failure both with and without type 2 diabetes.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
